Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported second quarter 2025 financial and ...

M&A deals announced worldwide in July included a rail merger, which is the largest transaction in the past 12 months based on ...

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

Get insights from Ligand Pharmaceuticals' Q2 2025 earnings—57% royalty revenue growth, raised guidance, and key partnerships driving long-term growth.

This acquisition centers on Ohtuvayre® (ensifentrine), Verona’s first-in-class inhaled COPD maintenance therapy, launched in August 2024 and already showing rapid adoption, including over $40 ...

Merck Expands Respiratory Portfolio with Verona Acquisition Attention then turns to Merck’s $10 billion acquisition of Verona Pharma, bringing Ohtuvayre—its FDA-approved COPD drug—into Merck’s ...

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the development of medicines for respiratory diseases. Merck will pay $10 billion in ...

Verona Pharma (NASDAQ: VRNA) PLC ADR has reached an all-time high, with its stock price climbing to $105.0. This milestone underscores a remarkable year for the company, which has seen a ...

On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio.

Investing in index funds is a safe way to grow your portfolio over the years. But there's a huge advantage to picking ...